Vliyanie ingibitorov dipeptidilpepti-dazy-4 na funktsional'noe sostoyanie miokarda u bol'nykh sakharnym diabetom 2 tipa


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Given the high prevalence of cardiovascular diseases in patients with type 2 diabetes mellitus (DM2), much attention is paid to the cardioprotective characteristics of glucose-lowering drugs. The article presents data for the effect of new drug vildagliptin, one of the incretin targeted therapies, on the functional state of myocardium in DM2 patients with coronary artery disease (CAD). Treatment with vildagliptin is accompanied by better glycemic control, reduction of glycosylated hemoglobin levels, improvement of exercise tolerance, increase of its threshold power, reduction of total time of ischemia, reduction of the size and severity of disorders of left ventricular myocardial perfusion.

Full Text

Restricted Access

References

  1. Александров А.А. Сахарный диабет: болезнь “взрывающихся" бляшек // Consilium medicum 2001. Т. 3. № 10. С. 464-68.
  2. Аметов А.С., Демидова Т.Ю. Принципы терапии сахарного диабета 2 типа в сочетании с артериальной гипертензией. Учебное руководство. М., 2001. 203 с.
  3. Nathan DM, Buse JB, Davidson MB, et al. Medical managment of hyperglycemia in type 2 diabetes: a consensus algoriym for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
  4. Le CD, Folsom AR, Pankow JS, Brancati FL. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004;109:855-60.
  5. Becker A, Bos G, de Vegt F, et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease 10-year follow-up of the Hoorn Study. Eur Heart J 2003;24:1406-13.
  6. Herman GA, Stevens C, Van Dyck K. Pharmacokinetic and pharmacodynamics of sita-gliptin, an inhibitor of dipeptidyl peptidase-lV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88.
  7. Ahren B. Vildagliptin: an inhibitor of dipeptidyl peptidase-lV with antidiabetic properties. Exp Opin Invest Drugs 2006;15:431-42.
  8. Ahren B. DPP-4 inhibitors. Best Pract Res. Clin Endocrinol Metab 2007;21(4):517-33.
  9. Pi-Sunyer FX, Schweier A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patiens with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-38.
  10. Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84.
  11. Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag 2010;6:541-48.
  12. Yusuf S, Hawken S, Ounpuu S, et al, for the lNTERHEART Study lnvestigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
  13. Mclntosh CH. Dipeptidyl peptidase lV inhibitors and diabetes therapy. Front Biosci 2008;13:1753-73.
  14. Kuritzky L. Managing type 2 diabetes in the primary care setting: beyond glucocentricity. Am J Med Sci 2010;340(2):133-43.
  15. Van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin lmproves Endothelium-Dependent Vasodilatation in Type 2 Diabetes. Diabetes Care 2011. Jul 25.
  16. Ban K, Hoefer J, Bolz SS, Drucker DJ, Husain M. Mechanisms underlying cardioprotective effects of glucagon-like peptide-1 in ischemia-reperfu-sion ingury. Canadian Cardiovascular Congress. Quebec City, October 20-24, 2007.
  17. Sokos GG, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12: 694-99.
  18. Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 1998;180:53-7.
  19. Garvey WT, Hardin D, Juhaszova M, Domingues JH. Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy. Am J Physiol 1993; 264:H837-44.
  20. Meszaros J. Effect of palmitoylcamitine on the passive electrical properties ofisolated guinea pig ventricular myocytes. Eur J Pharmacol 1991;194:107-10.
  21. Opie L. Glycolytic rates control cell viability in ischemia. J Appl Cardiol 1999;3:407-14.
  22. Cohn PF. Silent myocardial ischemia and infarction. New York: Marcel Dekker, lNC, 1993:129-30.
  23. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-65.
  24. Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007;100:824-29.
  25. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-99.
  26. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-65.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies